IN2015DN00694A - - Google Patents
Download PDFInfo
- Publication number
- IN2015DN00694A IN2015DN00694A IN694DEN2015A IN2015DN00694A IN 2015DN00694 A IN2015DN00694 A IN 2015DN00694A IN 694DEN2015 A IN694DEN2015 A IN 694DEN2015A IN 2015DN00694 A IN2015DN00694 A IN 2015DN00694A
- Authority
- IN
- India
- Prior art keywords
- glycoconjugates
- immunogenic compositions
- etec
- tein
- oxoethyl
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 108010078791 Carrier Proteins Proteins 0.000 abstract 1
- SPUWKECNTGTOFA-UHFFFAOYSA-N OC(=O)NCCSCC=O Chemical compound OC(=O)NCCSCC=O SPUWKECNTGTOFA-UHFFFAOYSA-N 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261684043P | 2012-08-16 | 2012-08-16 | |
| PCT/IB2013/056597 WO2014027302A1 (en) | 2012-08-16 | 2013-08-12 | Glycoconjugation processes and compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN00694A true IN2015DN00694A (enrdf_load_html_response) | 2015-06-26 |
Family
ID=49385307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN694DEN2015 IN2015DN00694A (enrdf_load_html_response) | 2012-08-16 | 2013-08-12 |
Country Status (32)
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9517274B2 (en) | 2012-08-16 | 2016-12-13 | Pfizer Inc. | Glycoconjugation processes and compositions |
| CN110787290B (zh) | 2014-01-21 | 2024-06-04 | 辉瑞公司 | 包含缀合荚膜糖抗原的免疫原性组合物及其用途 |
| PT3096786T (pt) * | 2014-01-21 | 2021-08-24 | Pfizer | Polissacáridos capsulares de streptococcus pneumoniae e conjugados dos mesmos |
| US11160855B2 (en) * | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| CN105934251A (zh) * | 2014-01-21 | 2016-09-07 | 辉瑞大药厂 | 肺炎链球菌荚膜多糖及其缀合物 |
| ES2701169T3 (es) | 2014-02-14 | 2019-02-21 | Pfizer | Conjugados glucoproteicos inmunogénicos |
| RU2760005C2 (ru) | 2014-03-13 | 2021-11-22 | Университет Базель | УГЛЕВОДНЫЕ ЛИГАНДЫ, КОТОРЫЕ СВЯЗЫВАЮТСЯ С IgM АНТИТЕЛАМИ ПРОТИВ МИЕЛИН-АССОЦИИРОВАННОГО ГЛИКОПРОТЕИНА |
| PT3244917T (pt) | 2015-01-15 | 2023-05-31 | Pfizer | Composições imunogénicas para utilização em vacinas pneumocócicas |
| JP6948951B2 (ja) * | 2015-05-04 | 2021-10-13 | ファイザー・インク | Ｂ群レンサ球菌多糖−タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用 |
| KR20240007690A (ko) * | 2015-06-08 | 2024-01-16 | 세럼 인스티튜트 오브 인디아 프라이비트 리미티드 | 다당류-단백질 접합체의 흡착을 개선시키는 방법 및 그로부터 수득된 다가 백신 제제 |
| JP6994453B2 (ja) * | 2015-07-21 | 2022-01-14 | ファイザー・インク | コンジュゲート化莢膜糖類抗原を含む免疫原性組成物、それを含むキットおよびこれらの使用 |
| AU2016323377B2 (en) * | 2015-09-16 | 2021-04-15 | Universität Basel | Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids |
| US10786561B2 (en) | 2015-11-20 | 2020-09-29 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| CN109862908B (zh) | 2016-08-05 | 2023-05-02 | 圣诺菲·帕斯图尔公司 | 多价肺炎球菌多糖-蛋白质缀合物组合物 |
| MY199342A (en) | 2016-08-05 | 2023-10-24 | Sanofi Pasteur Inc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| EP4309670A3 (en) | 2016-09-02 | 2024-07-17 | Sanofi Pasteur, Inc. | Neisseria meningitidis vaccine |
| KR20190103256A (ko) | 2016-12-30 | 2019-09-04 | 수트로박스, 인코포레이티드 | 비자연 아미노산을 갖는 폴리펩타이드-항원 접합체 |
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| US11413344B2 (en) | 2017-01-20 | 2022-08-16 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| US10729763B2 (en) | 2017-06-10 | 2020-08-04 | Inventprise, Llc | Mixtures of polysaccharide-protein pegylated compounds |
| AU2018280272C1 (en) * | 2017-06-10 | 2021-05-06 | Inventprise, Inc. | Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity |
| KR20250004911A (ko) * | 2017-09-07 | 2025-01-08 | 머크 샤프 앤드 돔 엘엘씨 | 담체 단백질에의 접합을 위한 폐렴구균 폴리사카라이드의 제제화 방법 |
| US11491216B2 (en) | 2017-09-07 | 2022-11-08 | Merck Sharp & Dohme Llc | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates |
| WO2019152925A1 (en) | 2018-02-05 | 2019-08-08 | Sanofi Pasteur Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| AU2019215212B2 (en) | 2018-02-05 | 2025-05-15 | Sk Bioscience Co., Ltd. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| BR112020018974A2 (pt) * | 2018-03-23 | 2021-01-05 | Koranex Capital | Glicoconjugados de precisão como ferramentas terapêuticas |
| JP2021522213A (ja) | 2018-04-18 | 2021-08-30 | エスケー バイオサイエンス カンパニー リミテッド | ストレプトコッカス・ニューモニエ莢膜多糖類及びその免疫原性接合体 |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| JP7239509B6 (ja) | 2019-02-22 | 2023-03-28 | ファイザー・インク | 細菌多糖類を精製するための方法 |
| EP3952906A1 (en) | 2019-04-10 | 2022-02-16 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
| CN111024832B (zh) * | 2019-10-29 | 2022-05-03 | 北京成大天和生物科技有限公司 | 多糖结合疫苗中残余NaCNBH3的离子色谱检测方法 |
| MX2022005252A (es) | 2019-11-01 | 2022-06-08 | Pfizer | Composiciones de escherichia coli y metodos de las mismas. |
| AU2021224078B2 (en) | 2020-02-21 | 2024-01-18 | Pfizer Inc. | Purification of saccharides |
| AU2021223184C1 (en) | 2020-02-23 | 2025-02-27 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| WO2022035816A1 (en) | 2020-08-10 | 2022-02-17 | Inventprise, Llc | Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f |
| KR20230043157A (ko) | 2020-09-17 | 2023-03-30 | 얀센 파마슈티칼즈, 인코포레이티드 | 다가 백신 조성물 및 이의 용도 |
| CA3199094A1 (en) | 2020-10-22 | 2022-04-28 | Pfizer Inc. | Methods for purifying bacterial polysaccharides |
| US12138302B2 (en) | 2020-10-27 | 2024-11-12 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| CA3199610A1 (en) | 2020-10-27 | 2022-05-05 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| MX2023005221A (es) | 2020-11-04 | 2023-05-16 | Pfizer | Composiciones inmunogenicas para uso en vacunas neumococicas. |
| US12357681B2 (en) | 2020-12-23 | 2025-07-15 | Pfizer Inc. | E. coli FimH mutants and uses thereof |
| WO2022234416A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| WO2022234405A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against bacterial and betacoronavirus infections |
| WO2022249107A2 (en) | 2021-05-28 | 2022-12-01 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2022249106A2 (en) | 2021-05-28 | 2022-12-01 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2024084397A1 (en) | 2022-10-19 | 2024-04-25 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| US20240181028A1 (en) | 2022-11-22 | 2024-06-06 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| EP4626405A1 (en) | 2022-12-01 | 2025-10-08 | Pfizer Inc. | Pneumococcal conjugate vaccine formulations |
| WO2024201324A2 (en) | 2023-03-30 | 2024-10-03 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2024214016A1 (en) | 2023-04-14 | 2024-10-17 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2024224266A1 (en) | 2023-04-24 | 2024-10-31 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2024241172A2 (en) | 2023-05-19 | 2024-11-28 | Glaxosmithkline Biologicals Sa | Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection |
| WO2025057078A1 (en) | 2023-09-14 | 2025-03-20 | Pfizer Inc. | Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof |
| WO2025186705A2 (en) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2025191415A1 (en) | 2024-03-11 | 2025-09-18 | Pfizer Inc. | Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US578573A (en) | 1897-03-09 | Brake-actuating mechanism | ||
| JPS60500673A (ja) | 1983-03-08 | 1985-05-09 | コモンウエルス セラム ラボラトリ−ズ コミツシヨン | 抗原活性を有するアミノ酸配列 |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
| IL101715A (en) | 1991-05-02 | 2005-06-19 | Amgen Inc | Recombinant dna-derived cholera toxin subunit analogs |
| JPH07507854A (ja) | 1991-12-23 | 1995-08-31 | ツォッヒェ，ミヒャエル | 油除去装置を備えたエンジン |
| DE69434079T2 (de) | 1993-03-05 | 2005-02-24 | Wyeth Holdings Corp. | Plasmid zur Herstellung von CRM-Protein und Diphtherie-Toxin |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| WO1998056942A1 (en) | 1997-06-12 | 1998-12-17 | Shin-Etsu Bio, Inc. | Production of non-native bacterial exopolysaccharide in a recombinant bacterial host |
| CA2344740C (en) | 1998-09-30 | 2011-11-22 | American Cyanamid Company | Mutant cholera holotoxin as an adjuvant |
| US6936258B1 (en) | 1999-03-19 | 2005-08-30 | Nabi Biopharmaceuticals | Staphylococcus antigen and vaccine |
| DE19926475A1 (de) * | 1999-06-10 | 2000-12-14 | Ktb Tumorforschungs Gmbh | Träger-Pharmaka-Konjugate |
| EA006947B1 (ru) * | 2001-01-23 | 2006-06-30 | Авентис Пастер | Поливалентная менингококковая полисахаридно-белковая конъюгированная вакцина |
| DE60234695D1 (de) | 2001-06-07 | 2010-01-21 | Univ Colorado | Mutantenformen von cholera holotoxin als adjuvans |
| BR0210216A (pt) | 2001-06-07 | 2004-06-08 | Wyeth Corp | Holotoxina do cólera imunogênica, mutante (ct-crm), composição imunogênica, métodos para aumentar a resposta imune de um hospedeiro vertebrado a um antìgeno, e para produzir uma holotoxina do cólera imunogênica, mutante, sequência ou molécula de ácido nucleico isolado e purificado, célula hospedeira, e, uso de uma holotoxina do cólera mutante |
| CN1394867A (zh) * | 2001-07-06 | 2003-02-05 | 中国科学院生态环境研究中心 | 可作药物的寡糖和其制备方法及含该寡糖的药物组合物 |
| AU2003277139A1 (en) * | 2002-10-03 | 2004-04-23 | Wyeth Holdings Corporation | Process for preparing monoprotected diols from symmetric diols |
| NZ561879A (en) * | 2003-03-07 | 2009-05-31 | Wyeth Corp | Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
| CA2519511A1 (en) | 2003-03-17 | 2004-09-30 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant and an antigen carrier protein |
| GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
| CA2562962A1 (en) * | 2004-04-14 | 2005-11-10 | Wyeth | Process for preparing rapamycin 42-esters and fk-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies |
| US7910753B2 (en) * | 2004-09-10 | 2011-03-22 | Anaspec Incorporated | Cyanine dyes and their applications as luminescence quenching compounds |
| DK1868645T3 (da) | 2005-04-08 | 2012-04-10 | Wyeth Llc | Multivalent pneumokok-sakkarid-protein-konjugat-sammensætning |
| GB0513069D0 (en) * | 2005-06-27 | 2005-08-03 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| TWI457133B (zh) * | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| SI1962899T1 (sl) * | 2005-12-22 | 2011-11-30 | Glaxosmithkline Biolog Sa | Pnevmokokna polisaharidna konjugatna vakcina |
| TW200806685A (en) * | 2006-02-21 | 2008-02-01 | Wyeth Corp | Processes for the convergent synthesis of calicheamicin derivatives |
| PE20080138A1 (es) * | 2006-03-07 | 2008-03-05 | Wyeth Corp | Procesos para preparar conjugados de polietilen glicol solubles en agua de inmunosupresores macrolidos |
| US20070253985A1 (en) | 2006-04-26 | 2007-11-01 | Wyeth | Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations |
| DE102006026436A1 (de) * | 2006-06-07 | 2007-12-13 | Continental Aktiengesellschaft | Verfahren und Messfahrzeug zur Ermittlung objektiver Reifeneigenschaften auf einer Fahrbahnoberfläche |
| AU2008265767B2 (en) * | 2007-06-20 | 2014-11-13 | Pfizer Ireland Pharmaceuticals | Modified polysaccharides for conjugate vaccines |
| RU2378015C2 (ru) * | 2008-04-02 | 2010-01-10 | Равшан Иноятович Атауллаханов | Конъюгат для иммунизации и вакцинации и способ повышения иммуногенности |
| EP3461496B1 (en) * | 2009-06-22 | 2023-08-23 | Wyeth LLC | Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
| WO2011000958A1 (en) * | 2009-07-03 | 2011-01-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compounds targeting the cation-independent mannose 6-phosphate receptor |
| ES2648249T3 (es) * | 2009-11-24 | 2017-12-29 | Grifols Therapeutics Inc. | Procedimientos, composiciones y kits de liofilización |
| US20130273098A1 (en) * | 2010-12-10 | 2013-10-17 | Jeffrey T. Blue | Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions |
| WO2013036847A1 (en) * | 2011-09-07 | 2013-03-14 | Prolynx Llc | Hydrogels with biodegradable crosslinking |
| US9517274B2 (en) * | 2012-08-16 | 2016-12-13 | Pfizer Inc. | Glycoconjugation processes and compositions |
| CN110787290B (zh) | 2014-01-21 | 2024-06-04 | 辉瑞公司 | 包含缀合荚膜糖抗原的免疫原性组合物及其用途 |
| ES2701169T3 (es) | 2014-02-14 | 2019-02-21 | Pfizer | Conjugados glucoproteicos inmunogénicos |
-
2013
- 2013-08-12 US US14/420,822 patent/US9517274B2/en active Active
- 2013-08-12 MX MX2015001992A patent/MX363511B/es unknown
- 2013-08-12 ES ES18183661T patent/ES2800479T3/es active Active
- 2013-08-12 BR BR112015003227-3A patent/BR112015003227B1/pt active IP Right Grant
- 2013-08-12 AU AU2013303826A patent/AU2013303826B2/en active Active
- 2013-08-12 PT PT181836610T patent/PT3421051T/pt unknown
- 2013-08-12 PE PE2015000211A patent/PE20150464A1/es active IP Right Grant
- 2013-08-12 SI SI201331739T patent/SI3421051T1/sl unknown
- 2013-08-12 IN IN694DEN2015 patent/IN2015DN00694A/en unknown
- 2013-08-12 SG SG11201500566XA patent/SG11201500566XA/en unknown
- 2013-08-12 JP JP2015527054A patent/JP6291495B2/ja active Active
- 2013-08-12 PL PL18183661T patent/PL3421051T3/pl unknown
- 2013-08-12 RU RU2016136630A patent/RU2724840C2/ru active
- 2013-08-12 CN CN201380049088.XA patent/CN104661684B/zh active Active
- 2013-08-12 PT PT13779365T patent/PT2885007T/pt unknown
- 2013-08-12 PL PL13779365T patent/PL2885007T3/pl unknown
- 2013-08-12 SI SI201331242T patent/SI2885007T1/sl unknown
- 2013-08-12 DK DK13779365.9T patent/DK2885007T3/en active
- 2013-08-12 MY MYPI2015700444A patent/MY167579A/en unknown
- 2013-08-12 HU HUE13779365A patent/HUE041381T2/hu unknown
- 2013-08-12 ES ES13779365T patent/ES2700824T3/es active Active
- 2013-08-12 RU RU2015103017A patent/RU2645071C2/ru active
- 2013-08-12 NZ NZ704490A patent/NZ704490A/en unknown
- 2013-08-12 EP EP13779365.9A patent/EP2885007B1/en active Active
- 2013-08-12 KR KR1020157006296A patent/KR101742406B1/ko active Active
- 2013-08-12 WO PCT/IB2013/056597 patent/WO2014027302A1/en active Application Filing
- 2013-08-12 DK DK18183661.0T patent/DK3421051T3/da active
- 2013-08-12 EP EP18183661.0A patent/EP3421051B1/en active Active
- 2013-08-12 HU HUE18183661A patent/HUE049531T2/hu unknown
- 2013-08-12 CA CA2881420A patent/CA2881420C/en active Active
- 2013-08-15 AR ARP130102904A patent/AR092368A1/es active IP Right Grant
- 2013-08-15 TW TW102129348A patent/TWI480049B/zh active
-
2015
- 2015-02-02 IL IL237066A patent/IL237066B/en active IP Right Grant
- 2015-02-04 PH PH12015500243A patent/PH12015500243B1/en unknown
- 2015-02-15 SA SA515360035A patent/SA515360035B1/ar unknown
-
2016
- 2016-11-09 US US15/347,034 patent/US9950054B2/en active Active
-
2018
- 2018-04-05 US US15/946,664 patent/US10583187B2/en active Active
-
2020
- 2020-01-28 US US16/774,309 patent/US11110160B2/en active Active
-
2021
- 2021-08-05 US US17/395,108 patent/US11723965B2/en active Active
-
2022
- 2022-07-22 LU LU00273C patent/LUC00273I2/fr unknown
- 2022-07-25 NL NL301188C patent/NL301188I2/nl unknown
- 2022-07-28 FR FR22C1037C patent/FR22C1037I2/fr active Active
- 2022-07-28 HU HUS2200034C patent/HUS2200034I1/hu unknown
- 2022-08-04 NO NO2022034C patent/NO2022034I1/no unknown
- 2022-08-05 FI FIC20220032C patent/FIC20220032I1/fi unknown
-
2023
- 2023-06-21 US US18/338,961 patent/US20230355735A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN00694A (enrdf_load_html_response) | ||
| MX340090B (es) | Analogos de spliceostatina. | |
| MY170719A (en) | Antibody-drug conjugates | |
| PH12014502826A1 (en) | Immunoconjugates comprising anti-cd79b antibodies | |
| EA032986B1 (ru) | Пирролобензодиазепины | |
| PH12015501000A1 (en) | Anti-notch3 antibodies and antibody-drug conjugates | |
| PH12014502825A1 (en) | Immunoconjugates comprising anti-cd22 antibodies | |
| MX2015002482A (es) | Composicion inmunogenica. | |
| MX350200B (es) | Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74. | |
| CL2016000468A1 (es) | Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso. | |
| MX2016008448A (es) | Conjugados de var2csa-farmaco. | |
| PH12014501039B1 (en) | Cytotoxic peptides and antibody drug conjugates thereof | |
| MY174813A (en) | Cytotoxic and anti-mitotic compounds, and methods of using the same | |
| MX2015008627A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| EP3566750A3 (en) | Conjugates comprising cell-binding agents and cytotoxic agents | |
| HK1204326A1 (en) | Enediyne compounds, conjugates thereof, and uses and methods therefor | |
| PH12015502645A1 (en) | Igg4 fc fragment comprising modified hinge region | |
| MA35816B1 (fr) | Dérivés d'aniline, leur préparation et leur application thérapeutique | |
| WO2014134457A3 (en) | Conjugates comprising cell-binding agents and cytotoxic agents | |
| WO2014134486A3 (en) | Conjugates comprising cell-binding agents and cytotoxic agents | |
| WO2012061012A3 (en) | 4-amino-2h-pyran-2-one analogs as anticancer agents | |
| IL269028A (en) | Boronized multifunctional drug-targeting conjugates, their uses and methods of preparation | |
| PH12018500014A1 (en) | Total synthesis of shishijimicin a and analogs thereof | |
| IN2013DE03665A (enrdf_load_html_response) |